Kinnate Biopharma Inc.
Total raised
$173 M
2 rounds on record
Latest round
$98 M
Jul 2020
First round on record
Dec 2019
Today
Private
No later event on record
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Kinnate Biopharma Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2020).
SEC Form D · Aug 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Aug 2020
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Foresite Capital Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Foresite Capital Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Foresite Capital Management IV, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Foresite Capital Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Foresite Capital Opportunity Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Foresite Capital Opportunity Management V, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Capital GP VII LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| OrbiMed Genesis GP LLC | Other | not stated | not stated | Held Series A, B and C preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Mark W. Meltz | Executive officer | Aug 2020 |
| Nima W. Farzan | Executive officer | Aug 2020 |
| Eric W. Murphy | Executive officer | Dec 2019 |
| Stephen W. Kaldor | Executive officer | Dec 2019 |
| Carl W. Gordon | Director | Aug 2020 |
| Dean W. Mitchell | Director | Aug 2020 |
| Jim W. Tananbaum | Director | Aug 2020 |
| Keith W. Flaherty | Director | Aug 2020 |
| Laurie W. Smaldone Alsup | Director | Aug 2020 |
| Michael W. Rome | Director | Aug 2020 |
| Nima W. Farzan | Director | Aug 2020 |
| Stephen W. Kaldor | Director | Aug 2020 |
| Bret W. Zbar | Director | Dec 2019 |
| Eric W. Murphy | Director | Dec 2019 |
| Stephen W. Kaldor | Promoter | Aug 2020 |